ARID1A and neoplasm: Shen et al showed that tumours with an ARID1A‐deficient ovarian cancer cell line origin in syngeneic mice displayed increased mutation load, enhanced levels of tumour‐infiltrating lymphocytes and up‐regulated PD‐L1 expression.